Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3300)
All Articles published online
|
Dec 14, 2010 (publication date) through Nov 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Wang DL, Gu DY, Huang HY, Xu Z, Chen JF. Irinotecan-involved regimens for advanced gastric cancer: A pooled-analysis of clinical trials. World J Gastroenterol 2010; 16(46): 5889-5894 [PMID: 21155012 DOI: 10.3748/wjg.v16.i46.5889] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v16/i46/5889.htm |
| Number | Citing Articles |
| 1 |
Koji Tanaka, Takeshi Omori, Toshiro Nishida. Materia Medica for Various Cancers. Evidence-based Anticancer Complementary and Alternative Medicine 2012; 2: 69 doi: 10.1007/978-94-007-1983-5_4
|
| 2 |
Ahmet Tunceroglu, Salma K Jabbour. Gastric cancer: past accomplishments, present approaches and future aspirations. Clinical Practice 2013; 10(1): 47 doi: 10.2217/cpr.12.82
|
| 3 |
Emil ter Veer, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven. The Use of (Network) Meta-Analysis in Clinical Oncology. Frontiers in Oncology 2019; 9 doi: 10.3389/fonc.2019.00822
|
| 4 |
Wei‐Xiang Qi, Zan Shen, Feng Lin, Yuan‐Jue Sun, Da‐Liu Min, Li‐Na Tang, Ai‐Na He, Yang Yao. Overall survival benefits for irinotecan‐containing regimens as first‐line treatment for advanced gastric cancer: An updated meta‐analysis of ten randomized controlled trials. International Journal of Cancer 2013; 132(2) doi: 10.1002/ijc.27775
|
| 5 |
Chao Zeng, Hang Zhou, Yang Wei, Liyang Wang, Hua Xie, Wenxiu Yao. Chemotherapy with or without irinotecan in patients with advanced or recurrent gastric cancer: a meta-analysis of randomized controlled trials. Chinese Medical Journal 2014; 127(5): 951 doi: 10.3760/cma.j.issn.0366-6999.20131490
|
| 6 |
Xiaolong Qi, Yanna Liu, Wei Wang, Danxian Cai, Wende Li, Jialiang Hui, Chuan Liu, Yanxia Zhao, Guoxin Li. Management of advanced gastric cancer: An overview of major findings from meta-analysis. Oncotarget 2016; 7(47): 78180 doi: 10.18632/oncotarget.12102
|
| 7 |
Mohamed Mesmoudi, Tarik Mahfoud, Samir Ahid, Nabil Ismaili, Saber Boutayeb, Hassan Errihani. Three Weekly Irinotecan and Bolus 5-Fluorouracil Combination in the First Line Treatment of Advanced Gastric Cancer - A Single Institution Experience. International Journal of Medicine and Surgery 2016; 3(1): 19 doi: 10.15342/ijms.v3i1.95
|
| 8 |
Jan Bornschein, Theodore Rokkas, Michael Selgrad, Peter Malfertheiner. Gastric Cancer: Clinical Aspects, Epidemiology and Molecular Background. Helicobacter 2011; 16(s1): 45 doi: 10.1111/j.1523-5378.2011.00880.x
|
| 9 |
Rosine Guimbaud, Christophe Louvet, Pauline Ries, Marc Ychou, Emilie Maillard, Thierry André, Jean-Marc Gornet, Thomas Aparicio, Suzanne Nguyen, Ahmed Azzedine, Pierre-Luc Etienne, Eveline Boucher, Christine Rebischung, Pascal Hammel, Philippe Rougier, Laurent Bedenne, Olivier Bouché. Prospective, Randomized, Multicenter, Phase III Study of Fluorouracil, Leucovorin, and Irinotecan Versus Epirubicin, Cisplatin, and Capecitabine in Advanced Gastric Adenocarcinoma: A French Intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) Study. Journal of Clinical Oncology 2014; 32(31): 3520 doi: 10.1200/JCO.2013.54.1011
|